CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition. |
On May 8, 2017, CytoSorbents Corporation (the Company) issued a
press release announcing its financial results for the quarter
and three months ended March 31, 2017. A copy of the press
release is furnished herewith as Exhibit 99.1.*
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | CytoSorbents Corporation Press Release, dated May 8, 2017. |
* The information in Item 2.02 of this Form8-K shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or
the Exchange Act, except as expressly set forth by specific
reference in such a filing.
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Recent Trading Information
CYTOSORBENTS CORPORATION (NASDAQ:CTSO) closed its last trading session down -0.20 at 4.30 with 148,712 shares trading hands.
